Physician profile
Amira Mahmoud Elsayed
NPI 1982720827
$2,786.85
in general payments reported to CMS, 2019-2025
30 companies · $380 in 2025
The $380 reported for 2025 was more than what 81% of Preventive Medicine/Occupational Environmental Medicine providers received nationally (typical 2025 total: $76.00).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $571 · 2023: $921 · 2024: $507 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $831.62 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $313.35 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Shield Therapeutics INC | $194.64 | 2023-2024 | Accrufer |
| Abbvie INC. | $129.24 | 2021-2024 | |
| Pfizer INC. | $118.29 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $112.64 | 2022-2024 | Farxiga, Airsupra |
| Amgen INC. | $98.55 | 2021-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $93.58 | 2023-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $73.74 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $68.63 | 2022 | |
| Exact Sciences Corporation | $66.72 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $65.88 | 2022-2024 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $61.27 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.85 | 2022-2023 | Xifaxan, Trulance |
| Abbott Laboratories | $49.36 | 2023 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.78 | 2021-2023 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $48.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $45.51 | 2024 | |
| Xeris Pharmaceuticals, INC. | $41.15 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $39.48 | 2022-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $38.72 | 2021-2023 | Nexletol |
| Axsome Therapeutics, INC. | $33.20 | 2025 | Sunosi |
| Edwards Lifesciences Corporation | $29.93 | 2025 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $27.92 | 2025 | Inspire |
| Saluda Medical Americas, INC. | $24.22 | 2024 | Evoke |
| Bayer Healthcare Pharmaceuticals INC. | $17.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.25 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $16.72 | 2022 | |
| Currax Pharmaceuticals LLC | $15.14 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amira Elsayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.